Prodotti competitors / Area HIV
HIV: Islatravir Clinical Program Overview
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Islatravir (formerly MK-8591, EFdA) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor. Islatravir is currently being evaluated for the treatment of HIV-1 infection in combination with other antiretrovirals, as well as for pre-exposure prophylaxis (PrEP) of HIV-1 infection as a single agent across a variety of formulations.
Please find a Islatravir Clinical Program Overviw at the following link
Link: https://www.merck.com/wp-content/uploads/sites/5/2021/07/ISL-Pipeline-Document-7-7-21.pdf
Grazie per il tuo feedback!